2021 CMSC Annual Meeting

Tag: BS1

Poster-Disease-modifying Therapy

Opportunities and Pitfalls in the Assessment of Brain Atrophy in Dimethyl Fumarate-Treated Relapsing Multiple Sclerosis Patients Using Real-World Data

Background: The majority of real-world data (RWD) on disease-modifying treatments (DMTs) for multiple sclerosis (MS) is based on clinical...

Read More

Poster-Case Reports / Case Series

Multiple Sclerosis-like Features in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Red Flag, Red Herring, or Regular Occurrence?

Background: MOG antibody-associated disease (MOGAD) is an inflammatory demyelinating disorder characterized by IgG antibodies against...

Read More

Poster-Case Reports / Case Series

Positive Outcome with Alemtuzumab in Hispanic Puerto Rican Woman with Highly Active Multiple Sclerosis after Various Failed Disease Modifying Therapies

Background: Multiple sclerosis (MS) is the most common autoimmune demyelinating disease of the central nervous system (CNS). It is an...

Read More

Platform-Psychosocial

Social-Cognitive Correlates of Physical Activity in Fatigued and Non-Fatigued Persons with Multiple Sclerosis

Background: There is interest in the application of behavioral interventions for increasing physical activity among adults with multiple...

Read More

Platform-Disease Modifying Therapies

COVID-19 Vaccine Response in People with MS Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab or Interferon Therapy

Background: COVID-19 is a potentially fatal respiratory illness, caused by the novel coronavirus, SARS-CoV-2, which developed into the...

Read More